Navigation Links
arGEN-X raises EUR 5 Million from PMV in Extension of EUR 32.5 Million Series B
Date:11/4/2013

since we started preclinical studies in April 2013. The results of these studies are encouraging and are giving us important insights to the potential of this unique approach for treating autoimmune diseases and enhancing the efficacy and duration of protein therapies."

"Having initiated clinical trials this year with ARGX-110, an anti-CD70 SIMPLE Antibody™, and with ARGX-111, an anti-cMet SIMPLE Antibody™, which are being tested in a range of cancers, we welcome this investment by PMV, which will enable us to accelerate the development of ARGX-113 towards the clinic. As a prominent local investor, PMV joins IWT and VIB as an important Flemish biotech stakeholder in our company."

Dr. Chris De Jonghe, Group Manager Venture Capital at PMV added: "We are impressed by the quality of the science and therapeutic programs at arGEN-X. The phenomenal productivity and capital efficiency of arGEN-X positions them as a leader in their field. With this investment, PMV further emphasizes its strategy to invest in outstanding companies in the Flemish biotech ecosystem. We are proud to become part of the arGEN-X story."            

About ABDEG and ARGX-113

ABDEG technology exploits the known binding interaction of antibody Fc regions with the neonatal Fc receptor (FcRn), which is expressed in endothelial, hematopoietic and epithelial cells, and is central to the process of antibody clearance from the circulation. Based on specific mutations contained within the Fc domain, ABDEGs have several clear therapeutic applications with exciting development potential. The first, exemplified by ARGX-113, uses mutation-bearing Fc fragments as products for the treatment of autoimmune disorders. The second introduces the ABDEG mutations into therapeutic antibody product Fc regions, creating a dual therapeutic effect mediated by the binding of both variable and constant regions. The third promotes
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
5. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
6. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
9. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
10. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
11. Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... PharmAthene, Inc. (NYSE Amex: PIP ) a ... threats, announced today that it will be hosting a ... at 4:30 p.m. E.T., to review the status of ... the United States is 866-788-0540. The dial-in number ...
... Results from two prospective, double-blind placebo controlled multi-center studies ... European efficacy and safety data in patients with focal ... at the American Academy of Neurology,s (AAN) 61st annual ... Merz Pharmaceuticals, which plans to file a Biologic License ...
Cached Medicine Technology:PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program 2Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 2Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 3Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 4Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 5
(Date:7/10/2014)... of the top public health concerns in the United ... as obese as of 2012. As health problems such ... to Twitter to discuss the problem. , A new ... at the Brown School at Washington University in St. ... tweets to track Twitter conversations about the issue of ...
(Date:7/10/2014)... EAST LANSING, Mich. For those students looking to ... answer may not be spending more time in a ... New Michigan State University research shows that students who ... on MSU,s campus during their freshman and sophomore years ... The research also indicated that students with memberships stayed ...
(Date:7/10/2014)... at the University of Huddersfield could help to improve ... food products such as butter, mayonnaise, yoghurt and ... an international profile for her work. , Katerina gained ... the University and now she has embarked on research ... Vassilis Kontogiorgos, she is investigating the potential of carbohydrates ...
(Date:7/10/2014)... A neuroscientist at Rutgers University-Newark says the human brain ... a finding that could provide a better understanding ... conditions that afflict an estimated 13.6 million Americans. , ... , Michael Cole, an assistant professor at the Center ... brain architecture of a person at rest is basically ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Want a higher GPA in college? Join a gym 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2
... panic. The following summarizes a new list of suggestions ... non-partisan National Center for Policy Analysis. Authored by NCPA ... full article is not sponsored by any commercial entity, ... Link to full article: http://www.ncpa.org/pdfs/Seven_Ways_Job_3-16-09-FINAL-A.pdf Here ...
... ... Newark, DE (PRWEB) March 17, 2009 ... ) have demonstrated that single embryos cultured under proper conditions ... successfully in women under age 35. In national results ...
... 17 eCardio Diagnostics ( www.ecardio.com ) announced ... Medicine initiative to provide a tailored offering to ... time an arrhythmia monitoring company has addressed the ... medical centers. "At eCardio, we work closely ...
... Leading HIFU device in Mexico for Minimally Invasive ... draws attention from elite urologistsCHARLOTTE, N.C., March 16 ... the Mexican and international entities of USHIFU, a ... of high intensity focused ultrasound (HIFU) technologies, will ...
... Boston, Mass. - Many households harbor a threat to ... tables and tables with glass panels. A review by ... publisher of Consumer Reports, finds that glass-table injuries aren,t ... could have been avoided had tempered glass been used. ...
... Less Than $1 MillionGross Margin Increases to 57.1%Programs ... & 2010First Quarter Sales Off to Strong StartMONROVIA, ... STAA ), a leading developer, manufacturer ... reported financial results for the fourth quarter and ...
Cached Medicine News:Health News:7 Ways to Keep Health Coverage If You Lose Your Job 2Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 2Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 3Health News:eCardio Diagnostics Launches Academic Medicine Initiative 2Health News:High Intensity Focused Ultrasound Physician Training Seminar in Mexico City 2Health News:Glass tables: An overlooked safety threat 2Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 2Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 3Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 4Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 5Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 6Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 7Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 8Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 9Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 10Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 11Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 12Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 13Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 14Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 15Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 16Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 17Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 18Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 19Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 20Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 21Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 22Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 23Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 24Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 25
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: